Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12623219rdf:typepubmed:Citationlld:pubmed
pubmed-article:12623219lifeskim:mentionsumls-concept:C0019564lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C0036751lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C0060993lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C0206128lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C0030685lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C0680255lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C0391871lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C1283071lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C1963578lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:12623219lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:12623219pubmed:issue2lld:pubmed
pubmed-article:12623219pubmed:dateCreated2003-3-7lld:pubmed
pubmed-article:12623219pubmed:abstractTextThe microdialysis technique was used to examine interactions between 5-HT(1A) and galanin receptors in the dorsal raphe nucleus (DRN), by measuring the extracellular levels of 5-HT in the ventral hippocampus of awake rats. The rats were pretreated with the 5-HT(1A) receptor agonist (R,S)-8-OH-DPAT (0.3 mg/kg, s.c.) or saline. 8-OH-DPAT caused a time-dependent reduction of basal 5-HT levels down to 43-48% at 40 min while at 140 min, the hippocampal 5-HT had returned to control values. At that time point, the rats received a second injection of 8-OH-DPAT or galanin (0.15, 0.5 and 1.5 nmol/0.5 microl) infused into the lateral ventricle. The second injection of 8-OH-DPAT caused a significantly smaller reduction of hippocampal 5-HT levels. In contrast, galanin at all three doses in the 8-OH-DPAT-pretreated groups, was significantly more potent in reducing 5-HT levels (maximal reduction to 74%, 52% and 49%, respectively) than it was in saline-pretreated rats (maximal reduction to 96%, 85% and 69%, respectively). The inhibitory effect of galanin (1.5 nmol) on extracellular 5-HT levels in the rat hippocampus was significantly attenuated by co-administration of the 5-HT(1A) receptor antagonists WAY-100635 (0.3 and 0.6 mg/kg s.c.) and, to a lesser extent, with pindolol (20 mg/kg s.c.). These data provide direct in vivo evidence of agonistic 5-HT(1A)-galanin receptor interaction at the presynaptic level. Furthermore, the findings indicate that a down-regulation of the somato-dendritic 5-HT(1A) autoreceptors, following their stimulation with 8-OH-DPAT and possibly also indirectly with 5-HT reuptake inhibitors, may be compensated by a subsequent 'sensitization' of the inhibitory galanin receptors in the DRN. Thus, the enhanced galanin receptor-mediated inhibition of 5-HT neurotransmission may contribute to the pathophysiology of depression or to the reduced and delayed efficacy of antidepressant therapies.lld:pubmed
pubmed-article:12623219pubmed:languageenglld:pubmed
pubmed-article:12623219pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:citationSubsetIMlld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12623219pubmed:statusMEDLINElld:pubmed
pubmed-article:12623219pubmed:monthFeblld:pubmed
pubmed-article:12623219pubmed:issn0028-3908lld:pubmed
pubmed-article:12623219pubmed:authorpubmed-author:YamaguchiMMlld:pubmed
pubmed-article:12623219pubmed:authorpubmed-author:OgrenS OSOlld:pubmed
pubmed-article:12623219pubmed:authorpubmed-author:KeilSSlld:pubmed
pubmed-article:12623219pubmed:authorpubmed-author:YoshitakeSSlld:pubmed
pubmed-article:12623219pubmed:authorpubmed-author:YoshitakeTTlld:pubmed
pubmed-article:12623219pubmed:issnTypePrintlld:pubmed
pubmed-article:12623219pubmed:volume44lld:pubmed
pubmed-article:12623219pubmed:ownerNLMlld:pubmed
pubmed-article:12623219pubmed:authorsCompleteYlld:pubmed
pubmed-article:12623219pubmed:pagination206-13lld:pubmed
pubmed-article:12623219pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:meshHeadingpubmed-meshheading:12623219...lld:pubmed
pubmed-article:12623219pubmed:year2003lld:pubmed
pubmed-article:12623219pubmed:articleTitleActivation of 5-HT(1A) autoreceptors enhances the inhibitory effect of galanin on hippocampal 5-HT release in vivo.lld:pubmed
pubmed-article:12623219pubmed:affiliationDepartment of Neuroscience, Karolinska Institutet, Retzius väg 8, 171 77 Stockholm, Sweden.lld:pubmed
pubmed-article:12623219pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12623219pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12623219pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12623219lld:pubmed